Key Points
- CEO Roger Susi sold 2,500 shares at an average price of $100.11 on March 10 for $250,275, leaving him with 2,247,500 shares (a 0.11% reduction in his stake).
- iRadimed beat quarterly estimates, reporting $0.54 EPS vs. $0.49 expected and $22.69M revenue vs. $21.60M, and set Q1 2026 guidance of $0.440–0.480 EPS and FY2026 guidance of $2.060–2.210 EPS.
- Dividend was increased to $0.20 per share quarterly (up from $0.17), equivalent to a $0.80 annualized payout with a ~0.8% yield and a ~45.7% payout ratio.
iRadimed Corporation (NASDAQ:IRMD - Get Free Report) CEO Roger Susi sold 2,500 shares of iRadimed stock in a transaction that occurred on Tuesday, March 10th. The shares were sold at an average price of $100.11, for a total transaction of $250,275.00. Following the transaction, the chief executive officer directly owned 2,247,500 shares in the company, valued at approximately $224,997,225. The trade was a 0.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
iRadimed Stock Down 1.2%
iRadimed stock opened at $98.94 on Wednesday. The firm has a market cap of $1.26 billion, a P/E ratio of 56.54 and a beta of 1.12. The business has a fifty day moving average of $100.08 and a two-hundred day moving average of $88.16. iRadimed Corporation has a twelve month low of $47.48 and a twelve month high of $107.90.
iRadimed (NASDAQ:IRMD - Get Free Report) last released its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 EPS for the quarter, topping the consensus estimate of $0.49 by $0.05. iRadimed had a return on equity of 23.83% and a net margin of 26.82%.The firm had revenue of $22.69 million during the quarter, compared to analyst estimates of $21.60 million. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. Equities analysts expect that iRadimed Corporation will post 1.66 earnings per share for the current year.
iRadimed Increases Dividend
The company also recently declared a quarterly dividend, which was paid on Friday, March 6th. Shareholders of record on Monday, February 23rd were issued a $0.20 dividend. This is an increase from iRadimed's previous quarterly dividend of $0.17. This represents a $0.80 annualized dividend and a yield of 0.8%. The ex-dividend date of this dividend was Monday, February 23rd. iRadimed's dividend payout ratio is presently 45.71%.
Wall Street Analyst Weigh In
IRMD has been the subject of several recent analyst reports. Weiss Ratings reissued a "buy (b-)" rating on shares of iRadimed in a report on Monday, December 29th. Lake Street Capital restated a "buy" rating and set a $120.00 price target on shares of iRadimed in a research note on Wednesday, February 11th. Finally, Roth Mkm reaffirmed a "buy" rating and issued a $120.00 price target on shares of iRadimed in a report on Tuesday, February 10th. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, iRadimed has an average rating of "Moderate Buy" and an average target price of $120.00.
View Our Latest Analysis on iRadimed
Hedge Funds Weigh In On iRadimed
Several hedge funds and other institutional investors have recently bought and sold shares of the business. Royal Bank of Canada raised its position in iRadimed by 14.7% during the 1st quarter. Royal Bank of Canada now owns 25,782 shares of the medical equipment provider's stock worth $1,354,000 after buying an additional 3,307 shares during the last quarter. AQR Capital Management LLC increased its stake in shares of iRadimed by 7.5% in the first quarter. AQR Capital Management LLC now owns 15,829 shares of the medical equipment provider's stock worth $831,000 after acquiring an additional 1,108 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of iRadimed by 5.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider's stock worth $252,000 after purchasing an additional 234 shares during the last quarter. Jones Financial Companies Lllp lifted its position in iRadimed by 8,568.5% during the first quarter. Jones Financial Companies Lllp now owns 11,269 shares of the medical equipment provider's stock valued at $591,000 after purchasing an additional 11,139 shares during the period. Finally, Goldman Sachs Group Inc. boosted its holdings in iRadimed by 1.1% in the first quarter. Goldman Sachs Group Inc. now owns 169,387 shares of the medical equipment provider's stock valued at $8,889,000 after purchasing an additional 1,821 shares during the last quarter. Institutional investors and hedge funds own 92.34% of the company's stock.
iRadimed Company Profile
(
Get Free Report)
iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company's core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.
In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
